Acutus Medical, Inc. (AFIB)
| Market Cap | 362.14M |
| Revenue (ttm) | 8.46M |
| Net Income (ttm) | -101.98M |
| Shares Out | 27.85M |
| EPS (ttm) | -8.94 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | April 16 |
| Last Price | $12.89 |
| Previous Close | $13.47 |
| Change ($) | -0.58 |
| Change (%) | -4.31% |
| Day's Open | 13.65 |
| Day's Range | 12.42 - 13.83 |
| Day's Volume | 176,787 |
| 52-Week Range | 12.32 - 38.99 |
New York, New York--(Newsfile Corp. - March 31, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Acutus Medical, Inc. ("Acutus" or the "Company") (NASDAQ: AFIB). Such investors ar...
CARLSBAD, Calif., March 30, 2021 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and t...
NEW YORK, March 30, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Acutus Medical, Inc. ("Acutus" or the "Company") (NASDAQ: AFIB). Such investors are advised to c...
CARLSBAD, Calif., March 18, 2021 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and t...
CARLSBAD, Calif., March 04, 2021 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and t...
Contract Pricing Now Widely Available for the AcQMap® High Resolution 3D Imaging and Mapping System Contract Pricing Now Widely Available for the AcQMap® High Resolution 3D Imaging and Mapping System
CARLSBAD, Calif., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Acutus Medical (Nasdaq: AFIB) today announced the appointment of David Roman as the company's Chief Financial Officer, effective March 1, 2021. In add...
CARLSBAD, Calif., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and tr...
CARLSBAD, Calif., Jan. 13, 2021 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and tr...
CARLSBAD, Calif., Dec. 28, 2020 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and tr...
About AFIB
Acutus Medical, Inc., an arrhythmia management company, designs, manufactures, and markets a range of tools for catheter-based ablation procedures to treat various arrhythmias in the United States and internationally. Its product portfolio includes novel access sheaths, transseptal crossing tools, diagnostic and mapping catheters, conventional and contact force ablation catheters, and mapping and imaging consoles and accessories, as well as supporting algorithms and software programs. Acutus Medical, Inc. was incorporated in 2011 and is based i... [Read more...]
| Industry Medical Devices | IPO Date Aug 6, 2020 |
| Stock Exchange NASDAQ | Ticker Symbol AFIB |
Financial Performance
In 2020, Acutus Medical's revenue was $8.46 million, an increase of 198.45% compared to the previous year's $2.84 million. Losses were -$101.98 million, 5.09% more than in 2019.
Analyst Forecasts
According to 5 analysts, the average rating for Acutus Medical stock is "Buy." The 12-month stock price forecast is 21.67, which is an increase of 68.11% from the latest price.